11^th European Biosimilars Congress

Biosimilars medications represent a new challenging frontier for the MENA (Middle East and North Africa) region healthcare landscape. While the region is suffering from political and economical challenges, the need for cost savings promised by the introduction of biosimilar medications has become of great interest to policy makers in the region. In spite of this, misconceptions about the biosimilar approval pathways, lack of robust regulatory frameworks, varying drug purchasing regulations and ongoing debate regarding switching, interchangeability and extrapolation is hindering these products from acheiving their maximum potential. Companies who want to enter the biosimilar business have to implement a diverse and complicated strategy to navigate through this turbulent landscape.